Compare Mesoblast Limited (MESO) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Schlumberger NV — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while Schlumberger NV trades at $46.38 (market cap $69.36B). The key difference: Schlumberger NV is far larger — about 32× Mesoblast Limited's market cap, and Schlumberger NV pays a 2.54% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | SLB | |
|---|---|---|
Market Cap | $2.17B | $69.36B |
Sector | Technology | Energy |
52-Week High | $20.96 | $58.01 |
52-Week Low | $12.88 | $31.72 |
Enterprise Value | $2.17B | $77.58B |
Dividend Yield | — | 2.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
SLB trades at $46.67, down 0.68% on the day, with a bearish technical signal from moving averages. The company reported revenue of $35.71 billion in 2025 with a net income margin of 9.26%, and has beaten EPS estimates in three consecutive quarters. Recent news highlights strategic alliances for data center power solutions and new contract wins, signaling growth in digital and offshore segments.
The outlook is supported by strong analyst consensus with a $62.83 price target and 84.85% buy ratings, but risks include oil price volatility and execution challenges. The stock offers value with a P/E of 20.7 and ROE of 14.57%, though margin compression from 2024 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
